Spark Investment Management LLC Buys Shares of 40,300 OncoCyte Corp (OCX)

Share on StockTwits

Spark Investment Management LLC bought a new position in OncoCyte Corp (NYSEAMERICAN:OCX) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 40,300 shares of the biotechnology company’s stock, valued at approximately $159,000.

Other institutional investors have also recently made changes to their positions in the company. Perkins Capital Management Inc. purchased a new position in shares of OncoCyte during the first quarter valued at $99,000. Virtu Financial LLC purchased a new position in shares of OncoCyte during the first quarter valued at $114,000. Vanguard Group Inc increased its stake in shares of OncoCyte by 3.8% during the third quarter. Vanguard Group Inc now owns 410,275 shares of the biotechnology company’s stock valued at $1,026,000 after buying an additional 15,115 shares during the period. Finally, Emerald Mutual Fund Advisers Trust purchased a new position in shares of OncoCyte during the first quarter valued at $9,836,000.

OCX has been the topic of several research reports. Chardan Capital restated a “buy” rating and set a $8.00 price target on shares of OncoCyte in a research note on Tuesday, April 2nd. Lake Street Capital raised their price objective on OncoCyte from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, January 29th. Janney Montgomery Scott raised OncoCyte from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 29th. Zacks Investment Research raised OncoCyte from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research report on Friday, January 25th. Finally, Piper Jaffray Companies started coverage on OncoCyte in a research report on Wednesday, February 13th. They set an “overweight” rating and a $6.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. OncoCyte currently has a consensus rating of “Buy” and a consensus target price of $6.00.

Shares of OCX stock opened at $4.48 on Friday. OncoCyte Corp has a 1-year low of $1.16 and a 1-year high of $6.92.

OncoCyte (NYSEAMERICAN:OCX) last issued its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01.

TRADEMARK VIOLATION WARNING: This news story was first published by Zolmax and is the sole property of of Zolmax. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://zolmax.com/investing/spark-investment-management-llc-buys-shares-of-40300-oncocyte-corp-ocx/3095039.html.

OncoCyte Profile

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Recommended Story: What is a conference call?

Want to see what other hedge funds are holding OCX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OncoCyte Corp (NYSEAMERICAN:OCX).

Institutional Ownership by Quarter for OncoCyte (NYSEAMERICAN:OCX)

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

PTC Therapeutics Target of Unusually High Options Trading
PTC Therapeutics Target of Unusually High Options Trading
Draegerwerk AG & Co KGaA  Given a €42.00 Price Target by Hauck & Aufhaeuser Analysts
Draegerwerk AG & Co KGaA Given a €42.00 Price Target by Hauck & Aufhaeuser Analysts
FY2019 Earnings Forecast for Mid-America Apartment Communities Inc  Issued By Capital One Financial
FY2019 Earnings Forecast for Mid-America Apartment Communities Inc Issued By Capital One Financial
Biohaven Pharmaceutical Holding Co Ltd  to Post Q2 2019 Earnings of  Per Share, Oppenheimer Forecasts
Biohaven Pharmaceutical Holding Co Ltd to Post Q2 2019 Earnings of Per Share, Oppenheimer Forecasts
Cato Corp’s  Same Store Sales Numbers Beat Analysts’ Expectations, Stock Rises by 0%
Cato Corp’s Same Store Sales Numbers Beat Analysts’ Expectations, Stock Rises by 0%
Ero Copper  Hits New 12-Month High After Analyst Upgrade
Ero Copper Hits New 12-Month High After Analyst Upgrade


 
© 2006-2019 Zolmax.